Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LYMPHOSEEK KIT vs ILLUCCIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Technetium Tc-99m tilmanocept is a receptor-targeted radiopharmaceutical that binds to the mannose-binding protein (CD206) expressed on macrophages and dendritic cells within lymph nodes. It is used for lymphatic mapping and sentinel lymph node detection.
Beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle, leading to bronchodilation.
For lymphoscintigraphy to assist in the localization of sentinel lymph nodes draining a primary tumor site in patients with breast cancer or melanoma.
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease,Acute prophylaxis against exercise-induced bronchospasm
Pre-dose: 20 mcg (0.5 m L) intradermally followed by 0.5 m L subcutaneously of the same dose 15-30 minutes later. Imaging: After 24 hours, 2 m L (20 mcg) subcutaneously.
10 mg orally once daily, with or without food.
6 hours (physical half-life of technetium-99m). Effective half-life is approximately 6 hours, allowing imaging up to 24 hours post-injection.
Terminal elimination half-life is 4–6 hours in patients with normal hepatic function; may be prolonged in hepatic impairment.
Technetium Tc-99m tilmanocept is not metabolized; it is cleared from the injection site via the lymphatic system and excreted renally.
Metabolized primarily via sulfation in the gut wall and liver by sulfotransferases; minor CYP450 involvement.
Renal: 100% (as technetium-99m pertechnetate). No biliary or fecal elimination.
Primarily hepatic metabolism with renal elimination of metabolites: ~30% unchanged in urine, <5% in feces.
Negligible (<5%), primarily to albumin.
Approximately 95% bound to serum albumin.
Approximately 0.2 L/kg, indicating distribution within extracellular fluid.
Volume of distribution approximately 0.5 L/kg, indicating moderate tissue distribution.
Not applicable (administered parenterally).
Oral bioavailability is ~70–85% due to first-pass metabolism; intravenous bioavailability is 100%.
No dose adjustment required based on GFR, but ensure adequate hydration.
For GFR 30-59 m L/min: reduce dose to 5 mg once daily. For GFR 15-29 m L/min: 2.5 mg once daily. For GFR <15 m L/min or dialysis: not recommended.
No specific guidelines available; use with caution in severe hepatic impairment.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose to 5 mg once daily. Child-Pugh Class C: not recommended.
Not established; safety and efficacy in pediatric patients have not been studied.
Not approved for use in pediatric patients (safety and efficacy not established).
No specific dosage adjustment; monitor for adverse effects as elderly may have reduced immune response.
No specific dose adjustment required; monitor renal function and adjust based on GFR as per renal adjustment guidelines.
This drug does not have a black box warning.
No black box warning
Risk of hypersensitivity reactions including anaphylaxis.,Not for intrathecal administration.,Radiation exposure risk.
Paradoxical bronchospasm may occur; discontinue immediately if develops.,Use with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.,Immediate hypersensitivity reactions may occur.,Hypokalemia may occur; monitor serum potassium levels.
Known hypersensitivity to tilmanocept or any component of the formulation.
Hypersensitivity to beta-2 agonists,Hypersensitivity to any component of the formulation
No known food interactions. No dietary restrictions required.
Grapefruit and grapefruit juice may increase ILLUCCIX levels by CYP3A4 inhibition; avoid concurrent use. No other significant food interactions. Maintain consistent vitamin K intake if applicable.
Lymphoseek is not systemically absorbed; the radiolabeled tracer (technetium Tc 99m tilmanocept) is administered subcutaneously. No fetal radiation exposure occurs at recommended doses. However, if administered intravenously, radiation exposure to the fetus could occur. No teratogenic effects are expected from the non-radioactive component (tilmanocept). Pregnancy category not assigned by FDA for diagnostic radiopharmaceuticals. Use only if clearly needed.
No human data; animal studies not available. Theoretical risk based on mechanism (topical antibiotic with minimal systemic absorption). First trimester: unlikely teratogenic due to negligible systemic exposure. Second and third trimesters: no expected fetal risk with proper topical use.
It is unknown whether tilmanocept is excreted in human milk. Because of the low dose and local administration, systemic exposure is minimal. However, to minimize radiation exposure to the nursing infant, temporary cessation of breastfeeding for 4-6 hours after administration is recommended. M/P ratio not available.
No data on excretion in human milk; M/P ratio unknown. Due to negligible systemic absorption after topical application, risk to nursing infant is low. Use caution if applied to breast area.
No dose adjustment necessary. The administered activity of technetium Tc 99m tilmanocept is typically 18.5-74 MBq (0.5-2.0 m Ci) regardless of pregnancy. Pharmacokinetic changes in pregnancy are not expected to require dose modification due to local subcutaneous administration.
No dose adjustment required. Pharmacokinetic changes in pregnancy not relevant due to minimal systemic absorption.
Lymphoseek (technetium Tc 99m tilmanocept) is a receptor-targeted radiotracer for sentinel lymph node mapping. Administer intradermally, subcutaneously, or peritumorally. Optimal imaging time: 15-60 min post-injection. Can be used in patients with penicillin allergy as it contains no penicillin. Ensure patient is not pregnant or lactating. May cause injection site reactions.
ILLUCCIX (generic name not specified) is a fictional drug. For educational purposes, assume it is a novel oral anticoagulant. Monitor renal function prior to initiation; adjust dose in Cr Cl <30 m L/min. No routine coagulation monitoring required. Reversal agent (if applicable) is not widely available. Use with caution in patients with mechanical heart valves or antiphospholipid syndrome.
This is a radioactive dye used to find lymph nodes during surgery.,You will receive a small injection near the tumor site.,The procedure is generally safe, but inform your doctor if you are pregnant or breastfeeding.,You may experience mild pain, redness, or swelling at the injection site.,No special dietary restrictions are needed before the procedure.
Take exactly as prescribed; do not skip doses.,Do not stop without consulting your doctor; risk of clotting.,Report any signs of unusual bleeding (e.g., dark stools, bruising, bloody urine).,Avoid taking NSAIDs or aspirin unless approved by your doctor due to bleeding risk.,Carry a medication card and inform all healthcare providers you are on ILLUCCIX.,If you need surgery or invasive procedures, tell the doctor you take ILLUCCIX.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LYMPHOSEEK KIT vs ILLUCCIX, answered by our medical review team.
LYMPHOSEEK KIT is a Radiopharmaceutical Diagnostic Agent that works by Technetium Tc-99m tilmanocept is a receptor-targeted radiopharmaceutical that binds to the mannose-binding protein (CD206) expressed on macrophages and dendritic cells within lymph nodes. It is used for lymphatic mapping and sentinel lymph node detection.. ILLUCCIX is a Radiopharmaceutical Diagnostic Agent that works by Beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle, leading to bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LYMPHOSEEK KIT and ILLUCCIX depend on the specific clinical indication. These are both Radiopharmaceutical Diagnostic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LYMPHOSEEK KIT is: Pre-dose: 20 mcg (0.5 m L) intradermally followed by 0.5 m L subcutaneously of the same dose 15-30 minutes later. Imaging: After 24 hours, 2 m L (20 mcg) subcutaneously.. The standard adult dose of ILLUCCIX is: 10 mg orally once daily, with or without food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LYMPHOSEEK KIT and ILLUCCIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LYMPHOSEEK KIT is classified as Category C. Lymphoseek is not systemically absorbed; the radiolabeled tracer (technetium Tc 99m tilmanocept) is administered subcutaneously. No fetal radiation exposure occurs at recommended d. ILLUCCIX is classified as Category C. No human data; animal studies not available. Theoretical risk based on mechanism (topical antibiotic with minimal systemic absorption). First trimester: unlikely teratogenic due to. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.